Supplementary table 1. Baseline and tumor characteristics of patients in the propensity score matched sample.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **Matched comparison** | | | |  |
|  |  | **Without thyroid incidentaloma N=321** | | **With thyroid incidentaloma**  **N=107** | | **SMD** |
|  |  | **N** | **%** | **N** | **%** |  |
| **Sex** | Male | 234 | 72.9 | 76 | 71 | -0.04 |
| **Age at diagnosis** | Median (IQR) | 68.0 (62.0-74.0) | | 68 (62.0-73.0) | | -0.08 |
| **Comorbidities** | Pulmonary | 59 | 18.4 | 20 | 18.7 | 0.01 |
|  | Cardiac | 68 | 21.2 | 23 | 21.5 | 0.01 |
|  | Vascular | 156 | 48.6 | 48 | 44.9 | -0.08 |
|  | Diabetes | 45 | 14.0 | 14 | 13.1 | -0.03 |
| **Histology** | Adenocarcinoma | 206 | 64.2 | 68 | 63.6 | -0.01 |
|  | Squamous cell carcinoma | 112 | 34.9 | 38 | 35.5 | 0.01 |
|  | Small cell carcinoma | 3 | 0.9 | 1 | 0.9 | 0,00 |
| **Primary tumor location** | Proximal | 17 | 5.3 | 5 | 4.7 | -0.03 |
| Mid | 57 | 17.8 | 20 | 18.7 | 0.02 |
|  | Distal | 195 | 60.7 | 61 | 57.0 | -0,08 |
|  | GEJ | 43 | 13.4 | 18 | 16.8 | 0.10 |
|  | Cardia | 7 | 2.2 | 2 | 1.9 | -0.02 |
|  | Multifocal | 2 | 0.6 | 1 | 0.9 | 0.04 |
| **Stage** | Stage 1 | 34 | 10.6 | 10 | 9.3 | -0.04 |
|  | Stage 2 | 77 | 24.0 | 25 | 23.4 | -0.01 |
|  | Stage 3 | 196 | 61.1 | 67 | 62.6 | 0.03 |
|  | Stage 4 | 14 | 4.4 | 5 | 4.7 | 0.02 |
| **Treatment** | No treatment | 8 | 2.5 | 2 | 1.9 | -0.04 |
|  | Surgery + nCRT | 140 | 43.6 | 48 | 44.9 | 0.03 |
|  | Surgery – nCRT | 17 | 5.3 | 5 | 4.7 | -0.03 |
|  | defCRT | 97 | 30.2 | 32 | 29.9 | -0.01 |
|  | defCRT followed by surgery | 59 | 18.4 | 20 | 18.7 | 0.01 |

SMD, standard mean difference; IQR, interquartile range; MDT, multidisciplinary team; nCRT, neoadjuvant chemoradiotherapy; defCRT; definitive chemoradiotherapy.